EPCAM and prostate carcinoma: Intriguingly, comparing the detection of cells of epithelial lineage (EpCAM+) in healthy controls and localized prostate cancer patients revealed the presence of CTCs in a minority of controls, accounting for the poor accuracy and sensitivity figures of the technique (53.2% and 40.0%, respectively) [63] (LE 2b).